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INTRODUCTION 
Colorectal carcinoma accounts for the 
majority of all gastrointestinal cancers and is the 
second leading site of cancer, excluding skin 
cancers, in overall incidence in the United 
States. 1 Cancer of the stomach, although de-
creasing in frequency, is still an important cause 
of morbidity and mortality. Unfortunately, data 
from large numbers of patients such as can be 
found in Cancer Patient Survival Report No. 5 
show only very modest increases in survival for 
patients with th\;!Se diseases in recent years. 2 
Gastric Carcinoma 
Most patients who develop gastric cancer 
have regional or distant disease at diagnosis. 
The presence of regional nodal involvement is 
almost synonymous with incurability since virtu-
ally all these patients are either non-resectable 
at the tim(;l of operation or rapidly develop sys-
temic recurrences. Any improvement in treat-
ment results would be expected to be produced 
by chemotherapy or immunotherapy rather than 
from localized forms 9f treatment. 
Fortunately, gastric carcinoma is relatively 
responsive to chemotherapeutic treatment, and 
at least four drugs have now been identified as 
active in treatment of this condition, namely 5-
fluorouracil (5-FU), Adriamycin, mitomycin-C, 
and semustine (methyl-CCNU). Although se-
mustine is the nitrosourea that has been most 
extensively used in the chemotherapy of gastro-
intestinal neoplasms, it is still an investigational 
drug and therefore is not always conveniently 
available. Other nitrosoureas that are on the 
market are probably similar in activity. 
Percentage of response and increase in 
survival with single-drug therapy have been 
modest, and for this reason the drugs have 
been combined into a variety of multiple-drug 
regimens. Most of the possible two and three-
drug combinations of the four active drugs have 
been tried. 
Table 1 shows response rates and sur-
vival figures for some of the most extensively 
tested combinations. The combination of 5-FU 
and semustine was one of the first advocated as 
being superior to 5-FU alone in the treatment of 
gastric carcinoma. More recently 5-FU plus 
Adriamycin plus mitomycin-C (FAM) combina-
tions have become more popular. The FAM 
regimen was initially reported to have a 50% re-
sponse rate in gastric carcinoma. The most re-
cent update of over 60 patients indicates that 
the response rate is holding at approximately 
43%. 3 
The FAM regimen (Table 2) is a well-toler-
ated treatment which gives partial or complete 
responses in about one half of the patients and 
benefits other patients by stabilizing the dis-
ease, resulting in prolonged survival for the pop-
ulation of treated patients. Quality of survival for 
many is good, and it is not uncommon to see 
responses lasting for over one year. 
One problem with the treatment is cu-
mulative marrow toxicity which is attributed to 
the mitomycin-C in the regimen . This tends to 
limit the treatment that can be given after the 
first few cycles. The cycles of treatment are sim-
ilar to other day-1 , day-8 treatments given every 
eight weeks. 
Other combinations of these drugs which 
utilize different doses and regimens have also 
been tried. Two of these used at the Sloan Ket-
tering Institute known as MIFA I and MIFA II con~ 
firm that these drugs in combination are effec-
90 / WAMPLER: RECENT ADVANCES IN GASTROINTESTINAL CANCER 
TABLE 1 
Combinations Used in Treatment of Gastric Carcinoma 
5-FLUOROURACIL + Semustihe 
5-FLUOROURACIL + ADRIAMYCIN + MITOMYCIN-C 
5-FLUOROURACIL + ADRIAMYCIN + Semustine 
5-FLUOROURACIL + MITOMYCIN-C 
ADRIAMYCIN + MITOMYCIN-C 
tive in the treatment of gastric cancer. 4 Table 1 
indicates treatment results of these and other 
combination treatments for gastric cancer. The 
median survival of patients with untreated ad-
vanced gastric carcinoma is four months or 
about 1 7 weeks from diagnosis . Since the fig-
ures in Table 1 show the survival in weeks from 
the time of treatment rather than diagnosis for 
the entire population of treated patients, not just 
the responders, one can see that a doubling of 
the survival time for the better combination is 
achievable . 
Dr Charles Moertel from the Mayo Clinic 
has recently analyzed data combined from sev-
eral cooperative groups. Using a statistical 
model, he concluded that 5-FU and Adriamycin 
contribute most to the treatment of gastric can-
cer. 5 This is a combination that has not received 
extensive use, and the projected value of the 
treatment needs confirmation in a large clinical 
trial. 
Colorectal Carcinoma 
Although there have been a number of at-
tempts to improve results in treatment of colo-
rectal cancer, most of these have been futile or 
have achieved only very modest success. The 
surgical treatment of colorectal cancer has 
been standard for several decades, and al-
though some recent studies indicate that pre-
DAY 1 
F 
A 
M 
TABLE 2 
FAM Regimen 
DAY 8 
F 
DAY 29 
F 
A 
DAY 36 
F 
F = 5-Fluorouracil 600 mg/M2 
A= Adriamycin 30 mg/M2 
M = Mitomycin-C 1 O mg/M 2 
Cycles of treatment are repeated every eight weeks. 
Response Rate 
9-45% 
21-43% 
36% 
Med. Survival Weeks 
17-25 
24-34 
22-30 
17 
operative ahd postoperative radiation therapy 
given adjuvantly in high-risk patients would be 
beneficial , particularly in patients with carci-
noma of the rectum, these suggestions have not 
met with widespread acceptance. 
Five-fluorouracil has been a standard 
treatment for colorectal cancer for 20 years , 
and one might summarize the clinical experi-
ence of a number of investigators' attempts to 
improve results by manipulating the 5-FU dose, 
schedule, or route of administration by simply 
stating that no schedule of treatment has been 
definitely shown to be superior to any other. 6 
The most common schedules used have been 
daily intravenous. treatments for five days re-
peated at five-week intervals or one intravenous 
treatment administered weekly . 
Administered orally , 5-FU gives response 
rates similar to the intravenous treatments of the 
drug . However, Moertel 7 has reported that the 
duration of response is shorter with the oral 
form of treatment. Absorption is erratic, averag-
ing about 50%. Because of these facts and be-
cause no oral form of treatment has been mar-
keted, use of this drug by this route of 
administration has not gained wide acceptance. 
Response rates with 5-FU in colorectal 
carcinoma average approximately 20%. Two 
forms of therapy which have a response rate 
above 1 0% are the nitrosoureas and mitomy-
cin-C . Other drugs have either had limited use 
in colorectal cancer or have given response 
rates of 1 0% or less, leaving only a few drugs 
that have a significant response rate in this dis-
ease. 
A number of combinations have been de-
vised for the treatment of colorectal carcinoma, 
the more extensively tested combinations 
being : 5-FU with semustine, mitomycin-C or hy-
droxyurea; 5-FU plus semustine plus vincristine; 
and 5-FU plus semustine plus dacarbazine. Re-
sponse rates for the combinations were initially 
WAMPLER: RECENT ADVANCES IN GASTROINTESTINAL CANCER / 91 
reported to exceed the results of 5-FU alone. 
The combination of 5-FU, semustine and vin-
cristine has been said to have response rates in 
the range of 35 to 40% by at least three differ-
ent groups. 8 •9 · 10 However, as additional studies 
and survival data are reported, the superiority of 
this combination over 5-FU alone has not been 
confirmed . 6 
Median survival for patients after proof of 
incurability is approximately 30 to 32 weeks 
with 5-FU alone, anq for the combinations the 
survival has be.en in the same range . Con-
sequently, the current consensus is that no 
combination of drugs for the treatment of colo-
rectal carcinoma has proved to be superior to 5-
FU alone. At this time other combinations are 
being tried which , it is hoped, will yield results 
surpassing those with only 5--FU. 
There is controversy regarding whether or 
not 5-FU alone increases survival in patients 
with colorectal carcinoma. To my knowledge, 
no prospective randomized trials have been 
done comparing 5-FU with no treatment in pa-
tients with advanced disease. Used many years 
ago for the treatment of advanced colorectal 
cancer, 5-FU was shown to yield responses and 
was felt to be beneficial , not only in achieving 
these responses but also in extenc;jing the life of 
the patient. No 9ne has since been willing to 
compare it to no treatment. 
One can easily demonstrate that 5-FU re-
sponders live longer than non-responders. Ad-
ditionally, retrospective analysis indicates that 
5-FU produces a modest increase in median 
survival in a population of treated patients. 
Moertel' s own data 1 1 demonstrated that 5-FU 
treated patients live longer throughout the entire 
survival curve than matched historical controls. 
This difference was discounted by Moertel who 
stated that there is no evidence showing that 5-
FU prolongs survival , attributing the difference 
to patient selection. This is only an opinion, and 
different interpretations are possible. 
A number of surgical adjuvant trials have 
been conducted in patients with colon and rec-
tal carcinomas. One of the earliest studies uti-
lized thiotepa or fluorodeoxyuridine (FUdR) after 
surgery. This particular study showed no effect. 
However, it is of interest that these patients, fol-
lowed over a decade, had no increase in carci-
nogenicity or other lc;3.te toxicity which could be 
ascribed to those treatments. 12 More recentiy a 
number of studies have been done utilizing 5-
FU in adjuvant treatment. In the non-random-
ized studies using historical controls , 5-FU was 
reported to produce a beneficial effect 13 · 14 ; in 
the randomized studies the 5-FU, in all cases, 
produced a slight prolongation of disea$e-free 
interval and survival in the treated group. 15- 19 
lnitialiy, the difference was judged not to be sta-
tistically significant; however, a recent statistical 
analysis using cumulative results involving 
larger patient numbers resulted in the con-
clusion that there is a statistically significant im-
provement, at least for some subsets of 5-FU-
treated patients in the adjuvant setting. Results 
of these studies are still pending . 
In an article in the Annals of Internal Medi-
cine,20 Ors Weiss and Devita stated that at the 
present time whether or not a patient receives 
adjuvant chemotherapy for colorectal carci-
noma is a decision that needs to be individ-
ualized for each patient. This is primarily be-
cause the results of 5-FU have been marginal at 
best, and the potential benefits of therapy may 
be overridden by a variety of other factors: dis-
ease stage (patients with Duke 's 82 or C stage 
lesions, eg, extension through the muscular 
layer and/ or invoived nodes are customarily 
treated); age of the patient; histologic grade of 
the tumor; economic factors; and convenience 
of travel to the treatment center for the patient. 
Following a trial of adjuvant treatment, the deci-
sion to continue treatment should be based on 
the patient's tolerance tempered by the knowl-
edge of limited survival benefit . 
Other Gas\rointestinal Tumors 
There are three uncommon types of gas-
trointestinal malignancies, all of which show sig-
nificant response rates to treatment with chemo-
therapy. 
Leiomyosarcomas are found in the stom-
ach and in the bowel . Recurrent or metastatic 
tumors respond to treatment with Adriamycin in 
approximately 30% of cases, and if combined 
with dacarbazine, the response rate may be 
1 0% higher. The treatment for metastatic 
leiomyosarcomas of the bowel is the same as 
for other metastatic sarcomas. 
Lymphomas also occur in the gastrointes-
tinal tract, and although their natural history 
may be somewhat different from those origina-
ting els~where, the chemotherapeutic treatment 
is basically similar. Where the histology predicts 
a favorable outcome, treatment would probably 
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consist of cyclophosphamide plus vincristine 
plus prednisone (COP) therapy and the unfavor-
able ones treated in addition with Adriamycin 
and possibly with Bleomycin . 
Carcinoid tumors are also responsive to 
chemotherapeutic treatment. About one third of 
these patients with advanced disease show ob-
jective responses to treatments with 5-FU and 
streptozotocin in combination. More recently 
Adriamycin has been used as a single agent. 
Treatment for this condition is still very much in 
a stage of evolution . 
Other Advances 
The biologic marker known as carcinoem-
bryonic antigen (CEA) which has been devel-
oped for clinical use in the last decade, ~as 
contributed materially to our ability to stage and 
follow patients with colorectal carcinoma. The 
initial hope was that the test would be useful as 
a diagnostic and screening tool. It has not 
proved to be very useful for this purpose. How-
ever, it has been found to be beneficial as a 
prognostic indicator. Patients with high levels of 
CEA prior to surgery will not do as well as pa-
tients with normal levels. It can also be utilized 
to assess adequacy of treatment or to evaluate 
disease recurrence and treatment response. It 
has been suggested that CEA-producing tu-
mors are inherently more likely to metastasize 
and are less controllable by the body's immune 
processes. This biological difference, if con-
firmed , will undoubtedly influence future treat-
ment strategies. 
Table 3 presents data taken from a study 
where 2, 3 7 2 patients of an unselected popu-
lation were screened for malignancy using CEA 
values. 2 1 Seventy-three of these patients were 
TABLE 3 
Use of CEA In Screening an Unselected Populatlon21 
23 72 people followed 5 years 
87% False Positive 64% False Negative 
CEA LEVEL 
< 5 ng/ml ::::5 ng / ml 
Developed a 16 11* 25 
CEA related Cancer 
Never developed 2000+ 62 
Cancer 
73 
(3% of total population) 
• two others were found to have incidental cancers not 
related to CEA evaluation. 
found to have elevated CEA levels above 5 ng / 
ml. Workup of these 73 patients resulted in the 
finding of malignancy in only 11 patients. Nine 
had a CEA-related malignancy and two had an 
incidental malignancy. The false-positive rate , 
therefore, was calculated at 87%. 
More disturbing than even the high false-
positive rate was the fact that 1 6 patients who 
were CEA-negative developed a CEA-associ-
ated cancer during the follow-up period for a 
false-negative rate of 64%. Only 3% of the 
2, 3 7 2 patients had elevated CEA levels which 
is consistent with the fact that 95% of a normal 
population are known to have CEA below 2. 5 
ng / ml. (In this population , 97% had the CEA 
level below 5 ng / ml.) The low incidence of can-
cer in this population of 2 , 3 7 2 resulted in the 
high false-negative percentage. CEA testing 
may play a role in screening certain high-risk 
populations, but it is not suitable as a screening 
mechanism for carcinoma of the colon in unse-
lected populations. 
It was originally thought that CEA would 
be specific for colon carcinoma since the anti-
gen was obtained from fetal colonic tissue. 
However, it was soon found that it is non-spe-
cific for colon carcinoma, being elevated in a 
variety of other malignancies including breast, 
lung , pancreas, stomach and bladder carcino-
mas, and in other malignancies. CEA is also 
elevated in patients with liver disease, pancre-
atic cysts, gastrointestinal polyps and other be-
nign conditions. The CEA is not specific for a 
particular primary site and is not even as spe-
cific as one would like for malignancy. 
With the understanding of certain charac-
teristics of biologic markers shown in Table 4, 
CEA tests can be used quite advantageously for 
a number of purposes. In general , biologic 
markers are non-specific for histologic types of 
neoplasms and often are not even specific for 
malignancy. The specificity and sensitivity tend 
to be inversely related . By developing a more 
sensitive assay, more positive results will be ob-
tained in patients with non-malignant conditions 
or with tumor types other than those antici-
pated . In contrast , if normal levels are drawn at 
a higher concentration, the test is more specific . 
For example, most patients with CEA over 1 0 
ng/ml will have a malignancy. 22 The percent-
age of patients with positive markers increases 
with the stage of the disease. Reports of CEA 
elevation in the 90% range are applicable only 
WAMPLER: RECENT ADVANCES IN GASTROINTESTINAL CANCER / 93 
TABLE 4 
Some Characteristics of Biologic Markers 
1 . In general biologic markers are non-specific for a 
histologic type of neoplasm and often are not even specific 
for malignancy. 
2. Sensitivity and specificity tend to be inversely related. 
3. The percentage of patients with positive markers 
increases with stage of disease. 
4. Not all patients develop positive markers. 
5. Marker status is not a dependent variable in relatipn to 
staging. 
to patients with advanced colorectal carcinoma. 
The figure is much lower for patients with local-
ized or regional disease only. 
Not all patients develop positive markers. 
Only those patients with certain phenotypic can-
cer cell expressions will show marker elevation . 
Other patients having histologically-similar tu-
mors will never be marker positive. Therefore, it 
is futile to attempt to manipulate a test to give 
results 1 00% of the time or to look for new 
markers that will do this. 
The percentage of CEA positivity in pa-
tients with colonic cancer was initially reported 
in excess of 90%. Later the percentage fell, the 
reason being that initially patients with ad-
vanced disease were tested , and in the later se-
ries more patients with earlier stages of disease 
were tested . 2 3 The percentage of CEA elevation 
directly correlates with the stage of disease; 
however, it is not a dependent variable, mean-
ing that the distribution of CEA positives in pa-
tients of various stages has a tendency toward 
randomness. In general, CEA and other bio-
logic markers are not dependent variables in re-
lation to the stage of disease or any other 
known prognostic factor. This means that prog-
nostication is improved by considering marker 
values along with stage, grade of tumor and 
other standard prognostic indicators. 
CEA is also useful in following colorectal 
patients for recurrence. The majority of patients 
who are found to have recurrences will have 
shown at least one CEA elevation greater than 
2 .5 ng/ml more than three months before doc-
umentation of recurrence. One study2 4 showed 
54% of the patients having this marker positive 
(>2 .5 ng/ml) more than three months prior to 
the documentation of recurrence. If a higher 
positive value (5 ng/ml) is used, 41 % will have 
an elevation three months before clinical tumor 
recurrence. An additional number of patients 
will have markers positive for three months or 
less prior to recurrence. The percentage of pa-
tients who show elevated CEA prior to recur-
rence of colon cancer is higher than in rectal 
cancer. (Table 5). 
In colon cancer only 14% are never ele-
vated prior to documentation of recurrence 
compared to 32% for rectal cancer. While this 
looks quite good as a tool for predicting recur-
rences, it has to be tempered by the fact that 
matched controls also have a high percentage 
of at least one elevated CEA value. The 
matched controls were patients with the same 
age, the same disease, and treatment, who had 
not had a recurrence during periods of equal 
follow-up. Some of these patients will eventually 
turn out to have a recurrence because it is 
known that the CEA can be elevated for as long 
as several years prior to recurrence. Some of 
these patients have random increases in CEA 
value; others have benign causes of the eleva-
tion. 
It is known that patients who receive blood 
products at the time of their surgery sometimes 
develop CEA elevations that plateau and later 
decrease2 5 secondary to hepatitis or undeter-
mined factors in the absence of acute or 
chronic liver disease. The problem in following 
these patients is to separate those who have 
random elevations or benign conditions from 
those who have a recurrence of malignancy. In 
order to distinguish those with random eleva-
tions, a CEA nomogram has been developed to 
indicate when values are statistically increased. 
Nomograms are published in the literature, 26 ·2 7 
but to be valid , each laboratory should con-
struct its own based on the precision of its test. 
While the nomogram is useful in differentiating 
patients who have a random increase from 
those with a true increase in CEA levels, repeat-
ing the value several times helps in making this 
differentiation. 
It is important to make a diagnosis of re-
currence earlier using CEA elevations. Some of 
these patients may be candidates for second 
surgery; others will be candidates for radiation 
therapy or chemotherapy. In considering pos-
sible patients for second surgery, it is necessary 
to separate those patients who are going to 
have an operable malignancy from those who 
have random fluctuation of the CEA, benign 
conditions, and inoperable lesions. Using the 
nomogram, one can distinguish most random 
fluctuations . Benign conditions tend to be 
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TABLE 5 
Percentage of Patients With 
Established Tumor Recurrence Who Exhibit 
CEA Elevations 24 
Primary 
Tumor 
Site 
COLON 
RECTUM 
COMBINED 
>2.5 ng / ml 
>3 mos before 
recurrence 
58 
42 
54 
>5 ng/ml 
>3 mos before 
recurrence 
45 
31 
41 
nomogram positive as are both operable and in-
operable malignancies. The operable malig-
nancies and random fluctuations would not be 
expected to have elevated liver enzymes. The 
degree of CEA elevation helps to discern the 
operable and inoperable malignancies. High 
elevations correlate with metastatic disease and 
more specifically with liver metastases. 
To determine operable cases one looks 
for patients with minimal elevations of CEA. In 
one series the mean elevation in the operable 
patients was 6.5 ng/ml compared to 15.5 ng / 
ml in those who had inoperable malignancy.28 
Additional information can be gained by looking 
at the character of the rise . If a benign condition 
exists, the CEA tends to plateau at levels usu-
ally less than 1 0 ng/ml. For any type of malig-
nant condition, an exponential rise occurs; the 
slope of the rise for those who are operable is 
less than that for the inoperable ones. The value 
is probably in the range of 0.5 ng/ml / mo or 
less for operable cancers and >1 ng/ml/mo 
for inoperable patients. 29 
>2.5 ng / ml 
<3 mos before 
recurrence 
28 
26 
29 
>5 ng / ml 
<3 mos before 
recurrence 
26 
32 
28 
Never 
elevated 
14 
32 
17 
A factor to be considered in the decision 
for reoperability is the interval between surgery 
and observed CEA elevation . The benign causes 
of the CEA elevations occur earlier after surgery 
than the operable malignancies. 21 Any CEA ele-
vations that occur early are more likely to be as-
sociated with inoperability. If they are caused by 
tumor, they probably are rising at a more rapid 
rate than those that occur later. Patients whose 
CEA elevations occur more than five months af-
ter surgery are more likely to be eligible for re-
exploration . These factors are summarized in 
Table 6. 
It is important to stress that the decision 
regarding reoperation is not based on just the 
CEA level. A careful determination must be 
made that the patient does not have clin ical 
metastatic disease by obtaining a chest x-ray, 
liver scan, serum chemistries , and other appro-
priate tests such as sonography, abdominal CT 
scan , and liver biopsy if other tests are nega-
tive. Careful monitoring and testing will exclude 
five sixths of the patients for consideration for 
TABLE 6 
Cause of CEA 
Elevation 
Random 
Fluctuation 
Benign 
Condition 
Operable 
Malignancy 
Inoperable 
Malignancy 
Nomogram 
- or± 
+ 
+ 
++ 
Differential Diagnosis of CEA Elevation 
Liver 
Enzymes 
-
Often 
+ 
-
Often 
+ 
Degree of 
Elevation 
Depends on 
Baseline Value 
Usually 
<1 Ong / ml 
Mean 
6.5 ng / ml 
mean 
15.5ng/ ml 
Character 
of Rise 
Not 
Verifiable 
Non 
Exponential 
(Plateau) 
Exponential 
Slope 
<1 ng / ml / mo 
Exponential 
Slope 
> 1 ng / ml / mo 
Time of 
Occurrence 
Post-Resection 
Random 
Median Time 
<5mo. 
) 
Median Time 
>5mo. 
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"second-look" surgery. Of the remaining one 
sixth, the resectability rate may be as high as 
30%. 30 Increasing the percentage of patients 
operated on will decrease the resectability per-
centage . The cure rate for the patients who are 
resected a second time is not known. 
A practical strategy for following patients 
with colorectal cancer with CEA assays is pre-
sented. Preoperative levels should be obtained 
for establishing a base line and serve as a prog-
nostic indicator. The test should be repeated 
postoperatively. Two weeks after surgery is 
both convenient and appropriate; however, if 
the CEA level has not returned to normal , the 
test should be repeated. 
Apparently not all CEA values return to 
normal promptly. If they remain elevated, it is 
important to establish a base line for nomogram 
analysis . Subsequently, values are obtained 
every two months for the early detection of re-
currence . After one year the test could be run 
less frequently. If a significant elevation is en-
countered outside the normal nomogram range , 
the test is repeated serially, two or three times, 
to verify elevation and determine, if possible, 
the character of the rise. Concurrently, the pa-
tient is evaluated carefully for metastatic dis-
ease. Selected patients may be candidates for 
surgery. 
In patients who have developed meta-
static disease, CEA can be used for evaluation 
of chemotherapeutic or radiotherapeutic re-
sponse. The CEA appears to be more corre-
lated with tumor burden if its value is below 1 00 
ng/ml. While this correlation is sometimes er-
ratic, it is the most valuable tool available in pa-
tients who do not have measurable disease. 
CONCLUSION 
Chemotherapy has produced significant 
improvement in treatment results for gastric car-
cinoma, but to date only minimal improvement 
has been achieved for colorectal carcinoma. 
Earlier application of radiation therapy, specifi-
cally preoperative and postoperative radiation 
therapy, particularly for patients with carcinoma 
of the rectum, is sufficiently attractive for further 
study. 
The primary area of improvement for pa-
tients with colorectal carcinoma has been in our 
ability to assess the status of the disease and in 
our beginning understanding of the biologic dif-
ferences in patients with the disease. Ultraso-
nography and CT scanning are relatively new 
procedures whose effect on the overall problem 
remains to be assessed . Carcinoembryonic an-
tigen testing is clearly an important advance, 
and there is every indication that other useful 
markers will be developed. 
The net effect of all these developments is 
the increased ability to select patients accu-
rately for given treatments and to follow treat-
ment results more precisely. It is known from 
previous experience that in those diseases in 
which the assessment of results is difficult, 
progress has been slow. Therefore, it is antici-
pated that more rapid improvements in treat-
ments in the coming years will ultimately be re-
flected in the overall survival statistics of these 
diseases. 
REFERENCES 
1. Cancer Facts and Figures. American Cancer Society, 
1980. 
2. AXTELL LM , ASIRC AJ, MYERS MH: Cancer Patient Sur-
vival Report Number 5. DHEW Publication no. (NIH) 
77-992. National Cancer Institute, Bethesda, MD, 
1976. 
3. MCDONALD JS, SCHEIN PS, WOOLLEY PV, ET AL: Five-
fluorouracil (5-FU), Mitomycin-C (MMC) and Adriamy-
cin (ADR) FAM Combination Chemotherapy Results in 
61 Patients with Advanced Gastric Cancer. Pro-
ceedings of the American Society of Clinical Oncology 
20 :396 , 1979. 
4. SCHAUER P, MAGILL GB, HOWARD J, ET AL: Combination 
Chemotherapy of Gastric CA with MIFA II or with 
AAFC-CPPD . Proceedings of the American Society of 
Clinical Oncology 20 :335, 1979. 
5 . MOERTEL CG , O'CONNELL MJ, LAVIN PT: Chemotherapy 
of Gastric Cancer. Proceedings of the American Asso-
ciation for Cancer Research 20:288 , 1979. 
6. MOERTEL CG: Current concepts in cancer chemother-
ap y of gastrointestinal cancer . N Engl J Med 
229:1049-1952 , 1978. 
7. HAHN RG , MOERTEL CG , SCHUTT AJ , ET AL: A double-
blind comparison of intensive course 5-fluorouracil by 
oral versus intravenous route in the treatment of colo-
rectal carcinoma. Cancer35:1031-1035 , 1975. 
8. MOERTEL CG , SCHUTT AJ , HAHN RG , REITMEIER RJ: 
Therapy of advanced colorectal cancer with a combi-
nation of 5-fluorouracil , methyl-1 , 3-cis (2-chloroethyl)-
1 -nitrosourea, and vincristine. JNCI 54: 69- 71 , 1 9 7 5. 
96 / WAMPLER: RECENT ADVANCES IN GASTROINTESTINAL CANCER 
9. FALKSON G, FALKSON HC: Flu6rouracil, methyl-CCNU, 
and vincristine jn cancer of the colon. Cancer 
38:1468~1470 , 1976. 
1 0. MACDONAl,D JS, KISNER OF, SMYTHE T, ET AL: Five-fluo-
rouracil (5-FU), methyl-CCNU and vincristine in the 
treatment of advanced colorectal cancer: Phase II 
study utilizing weekly 5-FU. Cancer Treat Rep 
60:1597-1600, 1976. 
11 . MOERTEL CG: Clinical management of advanced gas-
trointestinal cancer. Cancer 36:675-682 , 1975. 
1 2. GREENE MH , BOICE JD, KEEHN RJ , ET AL: Late Effects of 
Low Dose Adjuvant Chemotherapy in Colorectal Can-
cer. Proceedings of the American Society of Clinical 
Oncology 20:413 , 1979. 
13. LI MC, Ross ST: Chemoprophylaxis for patients with 
colorectal cancer: Prospective study with five-year fol-
low-up. JAMA 234 :2825-2828, 1976. 
14. MAVLIGIT GM, BURGESS MA, SEIBERT GB, ET AL: Prolon-
gation of postoperative disease-free interval ahd sur-
vival in human colorectal cancer by B.C.G. or B.C.G. 
plus 5-fluorouracil. Lancet 1 :1248, 1976. 
15. LAWRENCE W JR, TERZ JJ , HORSLEY S Ill: Chemotherapy 
as an adjuvant to surgery for colorectal cancer. Ann 
Surg 181 :616-623 , 1975 
1 6. HIGGINS GA JR, DWIGHT AW, SMITH JV, ET AL: Fluoroura-
cil as an adjuvant to surgery in carcinoma of the colon . 
Arch Surg 102:339-343, 1971 . . 
1 7. HIGGINS GA JR, HUMPHREY E, JULER GL, ET AL: Adjuvant 
chemotherapy in the surgical treatment of colorectal 
cancer. Cancer38:1461-1467 , 1976. 
18. BLIKHINA NG, GARIN AM, LIPATOU AM: Results of Five 
Year Observation for Patients Receiving 5-Fluorouracil 
After Radical Surgery for Carcinoma of the Colon and 
Rectum. Proceedings of the Second All-Union Cancer 
Chemotherapy Conference, Kiev, September 1974, 
pp 243-244. 
1 9. GRAGE TB, METTER GE, CORNELL GN , ET AL: The role of 
5-fluoroi.Jracil as an adjuvant to the surgical treatment 
of large bowel cancer. Adjuvant Therapy of Cancer, 
Salmon SE, Jones SE (eds). Amsterdam, E;lsevier / 
North Holland, pp 259-263, 1977. 
20. WEISS RB, DEVITA VT: Multimodal primary cancer treat-
ment (adjuvant chemotherapy): Current results and fu-
ture prospects. Ann Intern Med 91 :251-256, 1979. 
21. MACKAY IA : Use of Carcinoembryonic Antigen in 
Screening an Unselected Population: A Five Year Fol-
lowup in Clinical Application of Carcinoembryonic Anti-
gen Assay. Proceedings of a Symposium held in Nic;;e , 
France, Oct. 7-9, 1977, vol 439 , pp 419-421 , Am-
sterdam, Excerpta Medica International Congress Se-
ries, 1978. 
22. LOEWENSTEIN MS, ZAMCH!=CK N: Carcinoembryonic an-
tigen (CEA) levels in benign gastrointestinal disease 
states. Cancer42(3):1412-1418, 1978. 
23. ZAMCHECK N: The present status of CEA in diagnosis, 
prognosis, and evaluation of therapy. Can cer 
36:2460-2468 , 1975. 
24. RAMMING KP, MACINTYRE J, ZAMCHECK N, ET AL: Serum 
carcinoembryonic antigen (CEA) monitoring of patients 
at high risk for recurrence following surgery for colo-
rectal carcinoma. Proceedings of the American So-
ciety of Clinical Qncology 20:329, 1 979 . 
25. GITNICH GL, MOLNAR IG: Carcinoembryonic antigen: 
Trirnsmission by blood products. Cancer 42(3): 1 568-
1573, 1978. 
26 . MARTIN EW, JAMES KJ , HURTUBISE PE, ET AL: The use of 
CEA as an early indicator of gastrointestinal tumor re-
currence and second-look procedures . Cancer 
39:440-446, 1977. 
27 . RITTGERS RA, STEELE G JR , ZAMCHECK N, ET AL: Tran-
sient carcinoembryonic antigen (CEA) elevations fol-
lowing resection of colorectal cancer : A limitation in 
the use of serial CEA levels as an indicator for second-
look surgery JNCI 61 :315-318, 1978. 
28 . MINTON JP, MARTIN EW JR: The use of serial CEA de-
terminations to predict recurrence of colon cancer and 
when to do a second-look operation. Cancer 
42:1422-14 27, 1978. 
29 . STAAB HJ , ANDEVER A, STUMPF E, ET AL: Slope analysis 
of the postoperative CEA time course and its possible 
application as an aid in diagnosis of disease progres-
sion in gastrointestinal cancer . Am J Surg 136:322-
327 , 1978. 
30. WILSON RE , PERENCEVICH NP, OLSON R, ET AL: Colorec-
tal adenocarcinoma: Patterns of metastases after cura-
tive resection and the role of serial CEA measurements 
in their management. Eur Surg Res 1 0 : 11 5-11 6 , 
1978. 
WAMPLER: RECENT ADVANCES IN GASTROINTE;STINAL CANCER / 97 
